🚀 VC round data is live in beta, check it out!

XBiotech Valuation Multiples

Discover revenue and EBITDA valuation multiples for XBiotech and similar public comparables like BeyondSpring, PMV Pharma, IBT, InflaRx and more.

XBiotech Overview

About XBiotech

XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.


Founded

2005

HQ

United States

Employees

92

Financials (FY)

Revenue:
EBITDA: ($44M)

Market Cap

$71M

Valuation Multiples

Multiples.vc

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

XBiotech Financials

XBiotech reported last fiscal year revenue of — and negative EBITDA of ($44M).

In the same fiscal year, XBiotech generated ($44M) in EBITDA losses and had net loss of ($46M).

Revenue (LTM)


XBiotech P&L

In the most recent fiscal year, XBiotech reported revenue of and EBITDA of ($44M).

XBiotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See XBiotech forward-looking valuation multiples
LTMNTMLast FYFY 2026FY 2027FY 2028
EBITDAXXX($44M)XXXXXXXXX
Net ProfitXXX($46M)XXXXXXXXX

Financial data powered by Morningstar, Inc.

XBiotech Stock Performance

XBiotech has current market cap of $71M.

Market Cap Evolution


XBiotech's stock price is $2.33.

See XBiotech trading valuation data
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$71M-0.4%XXXXXXXXX$-1.49

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

XBiotech Valuation Multiples

XBiotech trades at 2.1x EV/EBITDA.

See valuation multiples for XBiotech and 15K+ public comps

EV / Revenue (LTM)


XBiotech Financial Valuation Multiples

As of April 11, 2026, XBiotech has market cap of $71M.

Equity research analysts estimate XBiotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

XBiotech has a P/E ratio of (1.6x).

LTMNTMLast FYFY 2026FY 2027FY 2028
Market cap (current)$71MXXX$71MXXXXXXXXX
EV (current)($91M)XXX($91M)XXXXXXXXX
EV/EBITDAXXX2.1xXXXXXXXXX
EV/EBITXXX1.6xXXXXXXXXX
P/EXXX(1.6x)XXXXXXXXX
EV/FCFXXX2.3xXXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified XBiotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

XBiotech Margins & Growth Rates

XBiotech's revenue in the last fiscal year grew by .

XBiotech's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.

See operational valuation multiples for XBiotech and other 15K+ public comps

XBiotech Operational Valuation Multiples

LTMNTMLast FYFY 2026FY 2027FY 2028
EBITDA GrowthXXX21%XXXXXXXXX
Revenue per EmployeeXXX$0.0MXXXXXXXXX
Opex per EmployeeXXX$0.6MXXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

XBiotech Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

EV/RevenueEV/EBITDA
LTM2026E2027ELTM2026E2027E
BeyondSpringXXXXXXXXXXXXXXXXXX
PMV PharmaXXXXXXXXXXXXXXXXXX
IBTXXXXXXXXXXXXXXXXXX
InflaRxXXXXXXXXXXXXXXXXXX
Fractyl HealthXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX

Valuation data powered by FactSet, Inc.

XBiotech M&A Activity

XBiotech acquired XXX companies to date.

Last acquisition by XBiotech was on XXXXXXXX, XXXXX. XBiotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See M&A valuation multiples

Latest Acquisitions by XBiotech

Acquired CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.

Start Free Trial

XBiotech Investment Activity

XBiotech invested in XXX companies to date.

XBiotech made its latest investment on XXXXXXXX, XXXXX. XBiotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See VC round multiples

Latest Investments by XBiotech

CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About XBiotech

When was XBiotech founded?XBiotech was founded in 2005.
Where is XBiotech headquartered?XBiotech is headquartered in United States.
How many employees does XBiotech have?As of today, XBiotech has over 92 employees.
Who is the CEO of XBiotech?XBiotech's CEO is Sushma Shivaswamy.
Is XBiotech publicly listed?Yes, XBiotech is a public company listed on Nasdaq.
What is the stock symbol of XBiotech?XBiotech trades under XBIT ticker.
When did XBiotech go public?XBiotech went public in 2015.
Who are competitors of XBiotech?XBiotech main competitors are BeyondSpring, PMV Pharma, IBT, InflaRx.
What is the current market cap of XBiotech?XBiotech's current market cap is $71M.
Is XBiotech profitable?No, XBiotech is not profitable.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial